HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Defective regulation of phosphatidylcholine-specific phospholipases C and D in a kindred with Tangier disease. Evidence for the involvement of phosphatidylcholine breakdown in HDL-mediated cholesterol efflux mechanisms.

Abstract
The negative correlation between coronary heart disease and plasma levels of HDL has been attributed to the ability of HDL to take up cellular cholesterol. The HDL3-induced removal of cellular cholesterol was reported to be impaired in fibroblasts from patients with familial HDL deficiency (Tangier disease, TD). In addition, we have recently shown that HDL3 stimulates the hydrolysis of phosphatidylcholine (PC) in cholesterol-loaded fibroblasts. To investigate whether this cell signaling pathway is involved in cholesterol efflux mechanisms, we compared the HDL3-induced PC hydrolysis in normal fibroblasts and in fibroblasts from a TD kindred, in whom the HDL3- and apolipoprotein A-I (apo A-I)-induced mobilization of cellular cholesterol was found to be reduced by 50%. The HDL3-induced formation of phosphatidic acid (PA) via PC-specific phospholipase D (PC-PLD) was markedly reduced by 60-80% in these cells, whereas the formation of diacylglycerol (DG) via PC-specific phospholipase C (PC-PLC) was two- to threefold enhanced. Defective regulation of PC-PLC and PC-PLD was similarly observed in response to apo A-I and endothelin, but not in response to the receptor-independent stimulation of PC hydrolysis by PMA. A Tangier-like PA and DG formation pattern could be induced in normal cells after preincubation with pertussis toxin, suggesting the involvement of a G-protein. The impaired mobilization of radiolabeled cellular cholesterol in TD cells could completely be overcome by increasing the PA levels in the presence of the PA phosphohydrolase inhibitor propranolol. Conversely, the inhibition of PA formation in the presence of 0.3% butanol as well as the inhibition of DG formation in the presence of the PC-PLC inhibitor D 609 reduced the mobilization of cellular cholesterol both in normal and in TD cells. Our data indicate that the coordinate formation of PA and DG via PC-PLD and PC-PLC is essential for efficient cholesterol efflux. The molecular defect in this TD kindred appears to affect an upstream effector of protein kinase C responsible for the G-protein-dependent regulation of PC-specific phospholipases.
AuthorsM Walter, H Reinecke, U Gerdes, J R Nofer, G Höbbel, U Seedorf, G Assmann
JournalThe Journal of clinical investigation (J Clin Invest) Vol. 98 Issue 10 Pg. 2315-23 (Nov 15 1996) ISSN: 0021-9738 [Print] United States
PMID8941649 (Publication Type: Journal Article)
Chemical References
  • 1,2-diacylglycerol
  • Apolipoprotein A-I
  • Bridged-Ring Compounds
  • Butanols
  • Diglycerides
  • Endothelins
  • Lipoproteins, HDL
  • Norbornanes
  • Phosphatidic Acids
  • Phosphatidylcholines
  • Phosphodiesterase Inhibitors
  • Thiocarbamates
  • Thiones
  • tricyclodecane-9-yl-xanthogenate
  • Propranolol
  • Type C Phospholipases
  • Phospholipase D
  • GTP-Binding Proteins
Topics
  • Apolipoprotein A-I (metabolism, pharmacology)
  • Bridged-Ring Compounds (pharmacology)
  • Butanols (pharmacology)
  • Cells, Cultured
  • Diglycerides (metabolism)
  • Endothelins (pharmacology)
  • Female
  • Fibroblasts (metabolism)
  • GTP-Binding Proteins (physiology)
  • Humans
  • Lipoproteins, HDL (analysis, metabolism)
  • Male
  • Middle Aged
  • Norbornanes
  • Pedigree
  • Phosphatidic Acids (metabolism)
  • Phosphatidylcholines (metabolism)
  • Phosphodiesterase Inhibitors (pharmacology)
  • Phospholipase D (genetics, metabolism, physiology)
  • Propranolol (pharmacology)
  • Signal Transduction (genetics, physiology)
  • Tangier Disease (genetics, metabolism)
  • Thiocarbamates
  • Thiones (pharmacology)
  • Type C Phospholipases (genetics, metabolism, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: